RECENT PLACEMENT

Occam Places Chau Cheng as VP of Investor Relations & Corporate Communications at Cytomx

Occam Places Chau Cheng as VP of Investor Relations & Corporate Communications at Cytomx

CytomX is a public, clinical-stage, oncology-focused biopharmaceutical company developing antibody drug conjugates. By pioneering a novel class of conditionally activated biologics, powered by its Probody® technology platform, CytomX’s goal is to transcend the limits of current cancer treatments by successfully leveraging therapeutic targets that were once thought to be inaccessible.

In early 2021, Occam recruited Chau Cheng, PhD as VP, Investor Relations & Corporate Communications. Previously, Chau led investor relations at Immunomedics, Inc. for over 15 years until the company’s acquisition by Gilead Sciences for $21B.

Related Placements

  1. Daniel Delubac as COO & CTO at Chemify
  2. Sanjeev Luther as President and CEO of Eterna Therapeutics
  3. Shakti Narayan, JD, PhD as CEO for Oncology Biotech Accent Therapeutics
  4. David Moller as Chief Scientific Officer of Variant Bio
  5. Daphne Karydas Recruitment to the Board of Elicio
About Occam Global

Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.